Company & Sponsor Intelligence

University of Oxford

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials18

Recruiting4

Completed7

Countries3

Therapeutic footprint

alzheimersautismdepressionneuroimmunologyother_neurologyparkinsonsschizophrenia

Indexed studies

NCT04047498Alternating DBS for Stepping Control in Parkinson's Disease
parkinsons · United KingdomNA

NCT03515733PF-04995274 and Emotional Processing in Treatment Resistant Depression
depression · United KingdomPHASE1

NCT02308982Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis
neuroimmunology · United KingdomPHASE3

NCT07771595Study of the Effects of Atomoxetine on Motivation
other_neurology · United KingdomPHASE4

NCT01364545Ketogenic Diets for Symptoms of Parkinson's Disease
parkinsons · United KingdomNA

NCT07434973Stratification and Treatment in Early Psychosis Study - PROMOTE
schizophrenia · AustriaPHASE3

NCT04121208MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease
alzheimers · United KingdomPHASE1

NCT04257331Parent Training to Reduce Behavioral Problems in Children With Autism Spectrum Disorder in China
autism · ChinaNA

NCT05357547Serotonin-receptor Agonism in Reward Processing
other_neurology · United KingdomPHASE2

NCT06670378Natural History Study for Patients With Nemaline Myopathy in the UK
other_neurology · United KingdomACTIVE_NOT_RECRUITING

NCT064123157T Amygdala and Citalopram Study
depression · United KingdomNA

NCT02926508Oxford Study of Prebiotics in Children
other_neurology · United KingdomNA

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →